Alexion Pharmaceuticals Stock News

Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $120.98, moving +1.78% from the previous trading session.

Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96%

The short interest data is out for November 30, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential

These innovative companies can make investors rich.

Polaris Capital Management leader Bernard Horn (Trades, Portfolio) released his third-quarter portfolio earlier this week.

These two biotech companies are safe bargains in today's volatile market.

These value stocks could be the prime beneficiaries of a young but thriving bull market.

The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential

Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.

BOSTON--(BUSINESS WIRE)--Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

Value investors, get those shopping carts ready.

These stocks can bring investors substantial returns for many years to come.

These companies are devoted to helping patients who don't have any other options.

Let's see if Alexion Pharmaceuticals, Inc. (ALXN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Owning innovative companies with clear-cut competitive advantages is a recipe for wealth creation.